Minimal residual disease monitoring in acute myeloid leukemia with non-A/B/D NPM1 mutations by digital polymerase chain reaction: feasibility and clinical use
暂无分享,去创建一个
H. Dombret | C. Preudhomme | S. de Botton | X. Thomas | C. Récher | R. Itzykson | N. Boissel | C. Berthon | O. Nibourel | E. Raffoux | A. Pigneux | C. Pautas | Juliette Lambert | P. Turlure | J. Vargaftig | K. Celli-Lebras | N. Duployez | L. Fenwarth | E. Fournier | Auriane Lesieur | Elise Fournier | J. Lambert
[1] Daniela Cilloni,et al. Digital PCR in Myeloid Malignancies: Ready to Replace Quantitative PCR? , 2019, International journal of molecular sciences.
[2] Torsten Haferlach,et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. , 2018, Blood.
[3] H. Dombret,et al. Randomized Phase II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First Remission. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Bob Löwenberg,et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.
[5] J. Cayuela,et al. Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] Yashma Patel,et al. Assessment of Minimal Residual Disease in Standard-Risk AML. , 2016, The New England journal of medicine.
[7] Mikael Kubista,et al. How good is a PCR efficiency estimate: Recommendations for precise and robust qPCR efficiency assessments , 2015, Biomolecular detection and quantification.
[8] N. Schmitz,et al. Molecular subtypes of NPM 1 mutations have different clinical profiles , specific patterns of accompanying molecular mutations and varying outcome in intermediate risk acute myeloid leukemia , 2015 .
[9] J. Cayuela,et al. Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. , 2013, Blood.
[10] E. Paietta,et al. Minimal residual disease in acute myeloid leukemia: coming of age. , 2012, Hematology. American Society of Hematology. Education Program.
[11] F. Lo‐Coco,et al. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] B. Kim,et al. Non-A type nucleophosmin 1 gene mutation predicts poor clinical outcome in de novo adult acute myeloid leukemia: differential clinical importance of NPM1 mutation according to subtype , 2009, International journal of hematology.
[13] Brunangelo Falini,et al. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. , 2007, Blood.
[14] B. Falini,et al. Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations , 2006, Leukemia.
[15] Paola Fazi,et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. , 2005, The New England journal of medicine.